Exploring how viruses that kill bacteria can improve treatment at mucosal surfaces.

Mechanistic insights into bacteriophage properties required for enhanced therapeutic potential at mucosal surfaces

NIH-funded research Baylor College of Medicine · NIH-11049075

This study is exploring how special viruses called bacteriophages can help fight off stubborn bacteria that don't respond to regular antibiotics, especially in places like your gut and lungs, to find new ways to keep you healthy without upsetting the good bacteria your body needs.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionBaylor College of Medicine NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11049075 on NIH RePORTER

What this research studies

This research investigates the use of bacteriophages, which are viruses that specifically target and kill bacteria, as a potential alternative to traditional antibiotics. The focus is on understanding how these phages can be effective against drug-resistant bacteria found in the complex ecosystem of human mucosal surfaces, such as those in the gut and respiratory tract. By identifying and characterizing phages that can thrive in these environments, the research aims to develop new therapeutic strategies that maintain the balance of beneficial bacteria while combating harmful pathogens. This approach seeks to address the growing issue of antibiotic resistance and improve patient outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals suffering from infections caused by antibiotic-resistant bacteria, particularly those affecting mucosal surfaces.

Not a fit: Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that effectively combat antibiotic-resistant infections without disrupting the beneficial microbiota.

How similar studies have performed: Previous research has shown promise in using bacteriophages as therapeutic agents, indicating that this approach could be a viable alternative to traditional antibiotics.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions bacteria infectionbacterial disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.